Canadian respiratory journal最新文献

{"title":"Efficacy and Safety of Anticoagulants in Patients With Idiopathic Pulmonary Fibrosis: A Meta-Analysis.","authors":"Shuo Yang, Di Xie, Jinyun Wang, Zhuomin Yang, Xiaoming Xue","doi":"10.1155/carj/4545181","DOIUrl":"10.1155/carj/4545181","url":null,"abstract":"<p><strong>Background: </strong>There is a known association between coagulation abnormalities and idiopathic pulmonary fibrosis (IPF), but it remains unclear whether anticoagulant treatment can extend the lifespan of IPF patients. This systematic review and meta-analysis aim to evaluate the efficacy and safety of anticoagulants in patients with IPF.</p><p><strong>Methods: </strong>A comprehensive search was conducted in PubMed, Embase, Cochrane, and Web of Science from their inception until June 30, 2024, with an English language restriction. We selected clinical studies that met the inclusion criteria after reviewing titles, abstracts, and full texts.</p><p><strong>Results: </strong>Three randomized controlled trials and five prospective studies, including 2185 patients, were analyzed. Compared to standard treatment, anticoagulants did not significantly affect overall mortality in IPF patients. However, excluding studies with warfarin monotherapy, other anticoagulants extended patient survival (OR = 0.56, 95% CI [0.33, 0.95], <i>p</i> = 0.03). Anticoagulants were associated with significantly increased adverse events (OR = 2.48, 95% CI [1.16, 5.32], <i>p</i> = 0.68) but improved lung function (forced vital capacity, FVC), increased lung capacity, and reduced plasma D-dimer levels. No significant differences were observed in the 6-min walk test (6MWT) or diffusing capacity of the lungs for carbon monoxide (DLCO).</p><p><strong>Conclusion: </strong>The study suggests that anticoagulants may extend the lifespan of IPF patients and improve lung function. However, they also increase the risk of adverse events such as bleeding. However, there is an increased risk of adverse events, such as bleeding. This may be due to the distinct mechanisms of action, risk profiles, and clinical outcomes of each drug, although the exact causes remain unclear. Further meta-analyses based on individual patient data are needed to confirm these findings.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"4545181"},"PeriodicalIF":2.1,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12714097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Impact of Peripheral and Respiratory Muscle Weakness in Patients With Interstitial Lung Disease: A Cross-Sectional Observational Study.","authors":"Jinliang Meng, Lun Zhang, Rui Xu, Yang Yang, Ruiqi Wang, Geyi Wen","doi":"10.1155/carj/7069021","DOIUrl":"10.1155/carj/7069021","url":null,"abstract":"<p><strong>Background: </strong>Muscle weakness is a clinically significant complication of interstitial lung disease (ILD) that worsens dyspnea, fatigue, and quality of life, but its epidemiology and clinical impact remain understudied.</p><p><strong>Methods: </strong>In this cross-sectional study of 107 ILD patients, peripheral muscle weakness was defined as handgrip strength (HGS) < 28.0 kg (males) or < 18.0 kg (females), and respiratory muscle weakness as maximal inspiratory pressure (MIP) < 80% predicted. Assessments included pulmonary function, echocardiography, diaphragm ultrasound, 6-min walk distance (6MWD), short physical performance battery (SPPB), quality of life, and psychological status. Multivariate logistic regression identified the predictors of muscle weakness.</p><p><strong>Results: </strong>Peripheral muscle weakness (66.4%) was associated with older age, lower BMI, worse pulmonary function, reduced 6MWD, and higher right ventricular systolic pressure (RVSP) (all <i>p</i> < 0.05). Calf circumference (OR 0.774, 95% CI 0.659-0.910) and 6MWD (OR 0.991, 95% CI 0.985-0.998) independently predicted peripheral weakness. Respiratory muscle weakness (46.7%) correlated with older age, lower BMI, impaired lung function, and higher peripheral weakness rates. Biomass fuel exposure (OR 7.855, 95% CI 1.587-38.890) and 6MWD (OR 0.742, 95% CI 0.648-0.850) were significant determinants. Both weakness types led to significant declines in diffusion capacity, physical function, and quality of life (<i>p</i> < 0.05), without ILD subtype differences.</p><p><strong>Conclusion: </strong>ILD patients with muscle weakness show impaired lung function, reduced physical capacity, and poorer quality of life. Calf circumference and 6MWD influence peripheral weakness, while biomass exposure and grip strength influence respiratory weakness.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"7069021"},"PeriodicalIF":2.1,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12714088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fezakinumab Alleviates Cigarette Smoke-Induced COPD by Suppressing the JAK1/STAT3 Pathway in Mice.","authors":"Yuwei Wang, Li Jin, Erche Yang, Xiaoqun Niu, Jianchuan Mao, Chaoqun Yuan, Yong Wang, Bo You, Lan Liu, Yanling Chai","doi":"10.1155/carj/3204642","DOIUrl":"10.1155/carj/3204642","url":null,"abstract":"<p><strong>Background: </strong>Elevated Th-22 cells and IL-22 are linked to chronic obstructive pulmonary disease (COPD); however, their mechanisms are not fully elucidated. This study aimed to evaluate the therapeutic effects of AG490 and fezakinumab in a cigarette smoke-induced COPD mouse model.</p><p><strong>Methods: </strong>Cigarette smoke-induced COPD mice were divided into Air, CS, AG490, and Fezakinumab groups. We assessed BALF TH-22 cell levels, IL-22 levels and lung tissue (lung tissue were taken from the same anatomical site of the left lower lobe) histopathological changes, IL-22R1 expression, and protein expression of Jak1, TYK2, STAT3, p-STAT3, Caspase3, Bax, and Bcl-2.</p><p><strong>Results: </strong>Th-22 and IL-22 expressions were higher in the CS group than those in the Air group. Both the AG490 and Fezakinumab groups had reduced levels compared with the CS group but remained higher than the Air group. Similarly, IL-22R1 expression was higher in the CS group than in the Air group, while both AG490 and Fezakinumab groups exhibited lower expression than the CS group. H&E staining indicated less severe airway remodeling, alveolar enlargement, and inflammatory cell infiltration in the AG490 and Fezakinumab groups compared with the CS group. Western blot analysis revealed higher levels of JAK1, p-STAT3, and Caspase3 and lower levels of STAT3 and Bcl-2 in the CS group than those in the Air group. Both AG490 and Fezakinumab groups exhibited lower levels of JAK1, p-STAT3, and Caspase3 than the CS group, while Fezakinumab groups exhibited lower levels of STAT3 and higher levels of Bcl-2 than the CS group.</p><p><strong>Conclusions: </strong>Th-22 cells and IL-22 play crucial roles in COPD pathogenesis. Fezakinumab and AG490 mitigate airway remodeling, alveolar enlargement, and pulmonary tissue inflammatory cell infiltration by modulating JAK/STAT pathways and apoptosis. These results suggest promising targeted therapies for COPD, potentially improving patient outcomes by addressing inflammatory mechanisms.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"3204642"},"PeriodicalIF":2.1,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12681421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HO-1-Enriched Lung-Derived Exosomes Mediate Cognitive Impairment in a Mice Model of COPD Exacerbation.","authors":"Guang Yu Yin, Jia Qiang Zhang, Zhou Ling Xie, Yun Xia Jin, Yu Wang, Feng Heng Qian","doi":"10.1155/carj/9976065","DOIUrl":"10.1155/carj/9976065","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to elucidate the impact of HO-1 on cognitive function in chronic obstructive pulmonary disease (COPD) exacerbation mice and uncover the bridging role of exosomes in the interorgan transport of HO-1 along the \"lung-brain\" axis, providing novel insights into COPD-associated cognitive dysfunction.</p><p><strong>Methods: </strong>HO-1(-/-) and wild-type mice were subjected to COPD exacerbation modeling through cigarette smoke and LPS exposure. Four groups were divided: (A) HO-1(+/+) mice; (B) HO-1(+/+) COPD exacerbation mice; (C) HO-1(-/-) mice; and (D) HO-1(-/-) COPD exacerbation mice. Cognitive function was assessed using the Morris water maze. Lung-derived exosomal HO-1 was quantified by Western blot. Fluorescently labeled exosomes from Groups A/B were injected into HO-1(-/-) mice via tail vein, generating four new cohorts: Group I: HO-1(+/+) mice injected with PBS; Group II: HO-1(-/-) mice injected with PBS; Group III: HO-1(-/-) mice injected with exosome (Exos) from Group A; Group IV: HO-1(-/-) mice injected with Exos from Group B; Exos biodistribution was tracked via in vivo imaging, followed by cognitive reassessment and HO-1 quantification.</p><p><strong>Results: </strong>Groups B/D showed reduced target quadrant dwell time versus Groups A/C, and Group B exhibited longer target quadrant dwell time than Group D. This shows that COPD exacerbation mice had cognitive decline, which was exacerbated by HO-1 deficiency. Group B exhibited higher HO-1 expression in lung exosomes than Group A. Injected exosomes accumulated preferentially in lungs over brain; Group IV displayed worse cognitive impairment than Group III.</p><p><strong>Conclusions: </strong>COPD exacerbation mice exhibit cognitive decline regardless of HO-1 expression status, but HO-1 knockout COPD exacerbation mice demonstrate more pronounced cognitive impairment. In COPD exacerbation mice, HO-1 expression is elevated in lung-derived exosomes. Cross-organ transduction experiments confirm that HO-1 can be transported via Exos and mediate cognitive dysfunction in COPD exacerbation mice. Thus, HO-1 exerts a concentration-dependent dual effect on brain function: protective at physiological levels yet detrimental when in excess.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"9976065"},"PeriodicalIF":2.1,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12680478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediating Role of BMI in the Association Between Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Mediation Analysis.","authors":"Zhende Luo, Lan Shu, Wei Yu","doi":"10.1155/carj/8606659","DOIUrl":"10.1155/carj/8606659","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the mediating role of body mass index (BMI) in the association between obstructive sleep apnea (OSA) and nonalcoholic fatty liver disease (NAFLD).</p><p><strong>Methods: </strong>In this cross-sectional study, 445 adult patients diagnosed with OSA at Zigong Fourth People's Hospital (2022-2024) were initially enrolled. After applying inclusion/exclusion criteria, 309 participants were included. Demographic characteristics and clinical parameters were collected. Correlation analysis and structural equation modeling (SEM) were utilized to assess BMI's mediation effect between OSA and NAFLD.</p><p><strong>Results: </strong>Correlation analyses revealed significant positive associations of BMI with both OSA (<i>r</i> = 0.296, <i>p</i> < 0.001) and NAFLD (<i>r</i> = 0.225, <i>p</i> < 0.001), while OSA and NAFLD were directly correlated (<i>r</i> = 0.199, <i>p</i> < 0.001). Mediation analysis demonstrated a significant indirect effect of OSA on NAFLD through BMI (<i>β</i> = 0.044, 95% CI: 0.004-0.084), accounting for 22.5% of the total effect. These findings remained robust after adjusting for covariates including sex, age, smoking status, hypertension, and diabetes mellitus.</p><p><strong>Conclusion: </strong>BMI serves as a critical mediator in the OSA-NAFLD relationship, suggesting that integrated weight management strategies should be incorporated into OSA therapy to reduce hepatic risk.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"8606659"},"PeriodicalIF":2.1,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145660488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Thoracic CT Severity Score and Scadding Staging With PFT, DLCO, and 6MWT in Patients With Sarcoidosis.","authors":"Muhammet Ali Takeş, Celalettin Korkmaz, Necdet Poyraz, Mücahit Yılmaz, Soner Demirbaş","doi":"10.1155/carj/1655729","DOIUrl":"10.1155/carj/1655729","url":null,"abstract":"<p><strong>Background: </strong>Chest computed tomography (CT) is widely used in the diagnosis and follow-up of diffuse parenchymal lung diseases like sarcoidosis. This study investigated the relationship between the Thoracic CT Severity Score (TCTSS) and parameters from pulmonary function tests (PFTs), diffusing capacity for carbon monoxide (DLCO), and the 6-min walk test (6MWT) in sarcoidosis patients, comparing its utility to the radiograph-based Scadding staging system.</p><p><strong>Methods: </strong>This retrospective study analyzed data from 60 sarcoidosis patients with concurrent chest radiograph, CT, PFT, DLCO, and 6MWT results. Patient demographics, TCTSS, Scadding stage, PFT parameters (forced expiratory volume in one second [FEV1], forced vital capacity [FVC], FEV1/FVC, PEF, and FEF25-75), DLCO, DLCO/VA, and 6MWT parameters (initial SpO2, final SpO2, desaturation percentage, distance, and predicted distance percentage) were collected. Correlations between these functional parameters and both TCTSS and Scadding stages were analyzed to compare the strengths of the two staging systems.</p><p><strong>Results: </strong>TCTSS showed moderate negative correlations with FEV1% (<i>r</i> = -0.44, <i>p</i> < 0.001), FVC% (<i>r</i> = -0.477, <i>p</i> < 0.001), DLCO (<i>r</i> = -0.522, <i>p</i> < 0.001), final 6MWT SpO2 (<i>r</i> = -0.417, <i>p</i>=0.001), and 6MWT% (<i>r</i> = -0.511, <i>p</i> < 0.001). Weaker correlations were observed between TCTSS and initial SpO2, desaturation, and 6MWT distance. The Scadding stage also demonstrated negative correlations with these parameters, although generally weaker for FEV1% and FVC%. TCTSS exhibited stronger negative correlations with FEV1%, FVC%, DLCO, and 6MWT% compared to Scadding staging. Conversely, the Scadding stage correlated more strongly with FVC (liters), FEV1 (liters), FEV1/FVC, DLCO/VA, initial SpO2, final SpO2, and 6MWT distance. Desaturation showed similar low-to-moderate positive correlations with both staging systems.</p><p><strong>Conclusions: </strong>This study demonstrates that TCTSS significantly correlates with most functional parameters, exhibiting stronger correlations for key measures (FVC%, FEV1%, DLCO, and 6MWT%) compared to the Scadding staging system. TCTSS is a valuable tool that warrants consideration in the follow-up of sarcoidosis patients. Our findings suggest that TCTSS could serve as a potential alternative or complementary system to the Scadding classification, potentially informing the development of a modified combined staging approach. Larger, multicenter studies are necessary to confirm these findings and further explore the role of TCTSS in sarcoidosis management.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"1655729"},"PeriodicalIF":2.1,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12657079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokine Expression Profiling in Idiopathic Pulmonary Fibrosis: Insights From Integrative Proteomic Analysis.","authors":"Chenyou Shen, Wei Wang, Guirong Li, Dong Wei, Xusheng Yang, Cheng Jiang, Yating Sheng, Yuan Chen, Jingjing Xu, Shugao Ye, Jingyu Chen","doi":"10.1155/carj/2272156","DOIUrl":"10.1155/carj/2272156","url":null,"abstract":"<p><strong>Introduction: </strong>Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease with a poor prognosis and no effective pharmacological treatments. Cytokines are a class of small-molecule proteins with diverse biological activities. Many cytokines-most notably transforming growth factor β-have been demonstrated to play an important role in IPF. However, a few studies have systematically described the relationship between cytokines and IPF.</p><p><strong>Methods: </strong>Lung tissues from controls and patients with IPF were collected during lung transplantation. The expression profiles of 440 cytokines in lung tissues were obtained using protein microarrays. Proteomic analysis was performed, and differentially expressed proteins (DEPs) were identified. Furthermore, an integrative bioinformatics analysis was performed and included functional enrichment analysis, protein-protein interaction (PPI) network construction, hub protein determination, immune cell infiltration analysis, potential drug prediction, and single-cell analysis. The hub protein expression was validated through Gene Expression Omnibus (GEO) database evaluation and immunochemical analysis.</p><p><strong>Results: </strong>32 DEPs were identified from the two groups. They were mainly enriched in cell chemotaxis, basal part of cell, and growth factor binding and were involved in PI3K-Akt signaling. The PPI network was constructed for the DEPs, and five hub proteins (FGF2, HGF, HBEGF, ERBB3, and ANGPT2) were identified. The immune infiltration analysis demonstrated a significantly higher percentage of resting NK cells in IPF lung tissue. The drug prediction analyses identified 13 potential candidates targeting the five hub proteins. The single-cell analysis predicted the cellular localization of each key cytokine.</p><p><strong>Conclusions: </strong>Using protein microarrays, we obtained comprehensive cytokine expression profiles in control and IPF lung tissues and conducted an integrated bioinformatics analysis of the proteomic data. Our findings may improve the comprehension of the role of cytokines in IPF and the underlying mechanisms. Moreover, they provide novel targets for developing safe and efficacious drugs for treating IPF.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"2272156"},"PeriodicalIF":2.1,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Hematocrit and Albumin Difference With Ventilator-Associated Pneumonia in Patients With Continuous Mechanical Ventilation: Evidence From MIMIC-IV Database.","authors":"Weiwei Mao, Chengyun Mu","doi":"10.1155/carj/6084081","DOIUrl":"10.1155/carj/6084081","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to investigate the relationship between the difference in hematocrit and albumin (HCT-ALB) and ventilator-associated pneumonia (VAP) among patients undergoing continuous mechanical ventilation.</p><p><strong>Methods: </strong>This research utilized the data from the Medical Information Mart for Intensive Care IV database. The primary outcome was VAP occurred. HCT-ALB levels were divided into three groups according to the quantile: < -1.10; -1.10-5.30; ≥ 5.30. All patients with continuous mechanical ventilation were categorized into two groups: those who developed VAP and those who did not. Univariate and multivariate logistic regression analyses were used to assess the relationship between HCT-ALB and VAP risk. Receiver operating characteristic (ROC) curves were used to evaluate the predictive ability. To further assess the robustness of the findings, subgroup analyses were performed.</p><p><strong>Results: </strong>In our study, a total of 3021 patients were enrolled, and among them, 361 patients experienced VAP. Multivariate logistic regression showed that taking HCT-ALB < -1.10 as reference, HCT-ALB ≥ 5.30 was linked to an increased risk of VAP in patients undergoing continuous mechanical ventilation (odds ratio = 1.36, 95% confidence interval: 1.02-1.81). The ROC curve demonstrated approximately moderate predictive ability. This association remained robust in subgroups of male, quick Sepsis-Related Organ Failure Assessment score ≤ 2, not using antibiotics, having oral care, and no history of trauma injury, chronic obstructive pulmonary disease, or respiratory failure.</p><p><strong>Conclusion: </strong>HCT-ALB, as an easily measurable indicator, was associated with the risk of VAP in patients with continuous mechanical ventilation.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"6084081"},"PeriodicalIF":2.1,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12615028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Comorbidities on Treatments and Outcomes of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.","authors":"Lisa Lim, Dylan Hansen, Jessica Fairley, Maryam Tabesh, Laura Ross, Nava Ferdowsi, Gene-Siew Ngian, Diane Apostolopoulos, Joanne Sahhar, Lauren V Host, Jennifer Walker, Gabor Major, Susanna Proudman, Wendy Stevens, Mandana Nikpour","doi":"10.1155/carj/5021789","DOIUrl":"10.1155/carj/5021789","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;Treatment recommendations for systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) have evolved from initial monotherapy to upfront combination therapy with agents, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors and prostanoids. In the presence of comorbidities, such as heart and lung disease, some clinicians have favoured monotherapy due to concerns about worsening ventilation-perfusion mismatch. We sought to evaluate whether comorbidity burden impacts prescribing practices, quality of life and survival in SSc-PAH.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We analysed prospectively collected data from participants recruited to the Australian Scleroderma Cohort Study (ASCS) between 2007 and 2024. Participants were included if they had PAH confirmed by right heart catheterisation. Data were collected on the presence of 12 comorbidities as defined by the Charlson Comorbidity Index (CCI), and prescription of PAH therapies, at PAH diagnosis and each subsequent annual visit. High morbidity was defined as a CCI score ≥ 4. With regard to prescribing practices, subgroup analysis was performed on two groups. The cardiac comorbidity group included patients with a diagnosis of angina, acute myocardial infarction, congestive cardiac failure or hypertension. The pulmonary comorbidity group included those with a diagnosis of chronic obstructive pulmonary disease or asthma. An additional subgroup of patients with SSc-related interstitial lung disease (ILD) was compared to those without ILD. Survival was evaluated using the Kaplan-Meier method and a multivariable Cox regression model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 2004 patients within the ASCS, 238 patients with SSc-PAH were included (11.8%). SSc-PAH patients had significantly higher CCI scores (3.0 vs. 2.0, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) and were more likely to have a high morbidity index (30.3% vs. 18.6% &lt;i&gt;p&lt;/i&gt; &lt; 0.001). Within the cohort of SSc-PAH patients, there were no significant differences between high and low morbidity patients with regard to clinical characteristics, autoantibody profile or internal organ manifestation. There was no difference in use of PAH medications between SSc-PAH patients with a low and high morbidity, with similar proportions receiving combination, monotherapy and no therapy, &lt;i&gt;p&lt;/i&gt;=0.10. This was also the case in a subgroup analysis of those with cardiac comorbidity, pulmonary comorbidity or SSc-ILD. When comparing SSc-PAH patients with high morbidity to those without using K-M survival analysis, there was higher all-cause mortality (&lt;i&gt;p&lt;/i&gt;=0.05). Univariable survival analysis showed no significant survival difference between SSc-PAH patients with high and low comorbidity burden. Combination therapy for PAH was associated with better survival compared to monotherapy (HR 0.60, 95% CI: 0.43-0.84, &lt;i&gt;p&lt;/i&gt;=0.003).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In this large cohort of SSc-PAH patients, the choice of treatments did n","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"5021789"},"PeriodicalIF":2.1,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12602041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LINC01214 Promotes Non-Small Cell Lung Cancer Through the miR-497-3p/HSP90AB1 Axis.","authors":"Guangfu Xu, Ling Zhang, Fei Li, Wenwen Han, Hailong Sun, Jiangtao Cao","doi":"10.1155/carj/5575392","DOIUrl":"10.1155/carj/5575392","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the potential of LINC01214 in providing prognostic and therapeutic insights, thereby offering valuable references for the research of non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>122 NSCLC subjects were recruited. The molecular level was quantified by qPCR and WB. Kaplan-Meier estimated the prognostic effects and Cox regression analyses the hazard ratio. The cell activities including proliferation, apoptosis, and migration/invasion were evaluated by CCK-8, flow cytometry, and Transwell. The regulatory axis of LINC01214/miR-497-3p/HSP90AB1 was verified by the dual luciferase reporter assay and rescue experiments.</p><p><strong>Results: </strong>LINC01214 increased both in the malignant tissues and cell lines of NSCLC. Mortality was increased in NSCLC patients with high LINC01214 levels. LINC01214 was an independent risk predictor of prognosis in NSCLC. Silencing of LINC01214 inhibited the NSCLC cell proliferation, migration, and invasion and promoted apoptosis. The abundance of miR-497-3p showed an opposite trend to LINC01214. LINC01214 could target miR-497-3p and negatively correlate with miR-497-3p. The inhibitory effect of LINC01214 on cell activity was reversed by miR-497-3p. HSP90AB1 was predicted and further confirmed as the target of miR-497-3p. The LINC01214/miR-497-3p/HSP90AB1 axis regulated NSCLC cell proliferation, migration, and invasion.</p><p><strong>Conclusion: </strong>LINC01214, a potential biomarker, contributed to the progression of NSCLC through the miR-497-3p/HSP90AB1 axis by promoting cell proliferation and motility.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"5575392"},"PeriodicalIF":2.1,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12591826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}